Project Grant R01MH137799
- Summary Under a $234,292 Project Grant awarded September 13, 2025, by the Fogarty International Center (CFDA 93.989: International Research and Research Training), Impact Research and Development Organisation will develop and pilot test a multilevel, community-based intervention to reduce Pre-Exposure Prophylaxis (PrEP) stigma and increase PrEP uptake among adolescent girls and young women (AGYW) ages 15–24 in western Kenya. The project addresses a critical public health gap, as AGYW represent...
- This Project Grant award of $665,225 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) aims to improve access and adherence to Pre-Exposure Prophylaxis (PrEP) among adolescent girls and young women in Uganda. The 5-year project, titled "SUUBI4PREP: Improving PrEP Access and Adherence Among Adolescent Girls and Young Women in Uganda", will combine peer support interventions with economic empowerment initiatives to address...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $381,487 to the University of Maryland, Baltimore (UMB) to assess the early implementation of long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) among adolescent girls and young women (AGYW) at high risk of HIV acquisition in Zambia. The key objectives are to: 1) Evaluate implementation determinants of CAB-LA...
- PHARMA-GIRL Project Grant Summary The University of California, San Francisco received a $408,643 Project Grant from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) for the period February 1, 2026 through January 31, 2028. The PHARMA-GIRL project conducts implementation science research to evaluate pharmacy-based HIV prevention and treatment service delivery models targeting adolescent...
- PROTECT AL: PrEP Optimization Through Enhanced Continuum Tracking The National Institute of Mental Health awarded the University of Alabama at Birmingham a $790,198 Project Grant on September 18, 2025, under the Mental Health Research Grants program (CFDA 93.242) to develop and implement PROTECT AL, a data-driven initiative designed to optimize HIV pre-exposure prophylaxis (PrEP) utilization across Alabama's high-incidence areas. The project, extending through May 31, 2030, delivers a...
- This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $653,677.00 to the University of California, Los Angeles (UCLA) to implement a cluster randomized control trial (CRCT) to test the impact of a long-term, dynamic choice intervention on 12-month viral suppression for individuals with HIV treatment interruption in Malawi. The project, titled "Ongoing Dynamic Choice to Address HIV...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $188,995.00 to the University of Pittsburgh under the Drug Use and Addiction Research Programs (CFDA 93.279) on August 15, 2025, for the "Prescribe to Prevent HIV" (P2PH) trial, with a completion date of July 31, 2028. This project grant supports implementation research aimed at addressing the urgent health crisis of severe injection-related infections (SIRI), including HIV, among the estimated...
- This $5.37 million project grant from the National Institutes of Health National Institute on Drug Abuse will fund the development of a context-aware digital adherence intervention called SMARTSTEPS to improve pre-exposure prophylaxis (PrEP) adherence among men who have sex with men with substance use disorder. The grant will support two phases. Phase I will inform the specification of an algorithm that utilizes digital phenotyping data from a smartphone app to anticipate non-adherence based...
- Federal Project Grant Award Summary New York University School of Medicine received a $771,043 Project Grant awarded on March 15, 2026, from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds a hybrid Type II implementation-effectiveness trial designed to improve HIV prevention and substance use treatment outcomes for people who inject drugs. The primary deliverable is a social network-based peer change agent intervention called...
- This Project Grant award in the amount of $431,712, funded by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to improve HIV testing among children under five in rural Uganda. The primary goal is to engage with traditional healers to facilitate HIV counseling and testing via oral swab antigen tests for this vulnerable pediatric population. The award supports two key activities: 1) determining barriers and...
PEER-LED DYNAMIC CHOICE HIV PREVENTION FOR WOMEN AT ELEVATED HIV RISK IN UGANDA - PROJECT SUMMARY/ABSTRACT DESPITE REMARKABLE PROGRESS IN HIV TESTING AND TREATMENT, HIV INCIDENCE REMAINS UNACCEPTABLY HIGH AMONG WOMEN AND GIRLS IN EASTERN AND SOUTHERN AFRICA. IN UGANDA, HIV INFECTIONS ARE CONCENTRATED AMONG WOMEN AT ELEVATED HIV RISK DUE TO FACTORS SUCH AS WORKING IN VENUES WHERE TRANSACTIONAL SEX IS COMMON. ALTHOUGH ORAL PRE-EXPOSURE PROPHYLAXIS (PREP) IS BEING SCALED UP, MANY WOMEN AT ELEVATED HIV RISK FACE BARRIERS TO ACCESSING ORAL PREP AT HEALTH FACILITIES AND TO STORING AND ADHERING TO PILLS. A NEW ERA OF CHOICE IN BIOMEDICAL HIV PREVENTION, INCLUDING THE DAPIVIRINE VAGINAL RING (DVR) AND LONG-ACTING CABOTEGRAVIR (CAB-LA), PRESENTS AN OPPORTUNITY TO REDUCE NEW INFECTIONS. POST-EXPOSURE PROPHYLAXIS (PEP) COULD FILL GAPS IN COVERAGE. AS NEW CHOICES IN HIV PREVENTION ARE ROLLED OUT, STRATEGIES ARE NEEDED TO EMPOWER WOMEN TO CHOOSE AMONG PREVENTION PRODUCTS AND SUPPORT SUSTAINED USE. OUR STUDY TEAM DEVELOPED AND TESTED THE SEARCH DYNAMIC CHOICE HIV PREVENTION (DCP) INTERVENTION (INCLUDING PRODUCT CHOICE: PREP OR PEP, WITH OPTION TO SWITCH OVER TIME, CHOICE OF FACILITY OR COMMUNITY-BASED VISITS, AND PROVIDER TRAINING ON PATIENT-CENTERED CARE). IN THREE RANDOMIZED TRIALS IN OUTPATIENT, ANTENATAL, AND COMMUNITY SETTINGS, DCP INCREASED TIME COVERED BY A BIOMEDICAL PREVENTION PRODUCT OVER TWO-FOLD COMPARED TO STANDARD OF CARE PREVENTION SERVICES. HOWEVER, THERE WERE GAPS IN ENGAGING WOMEN WHO WORK IN VENUES IN THE DCP MODEL. WE HAVE CONDUCTED FORMATIVE WORK, IN COLLABORATION WITH OUR COMMUNITY ADVISORY BOARD, TO TAILOR THE EFFECTIVE DCP INTERVENTION TO FURTHER REACH AND ENGAGE WOMEN AT ELEVATED HIV RISK. KEY RECOMMENDATIONS FROM THIS WORK INCLUDED INCREASING ACCESS TO LONG- ACTING PRODUCT CHOICES, EXPANDING OUTREACH BEYOND FACILITIES, AND EXTENDING EXISTING PEER SERVICES FOR HIV PREVENTION. PEER APPROACHES ARE RECOMMENDED IN NATIONAL GUIDELINES AND ARE BEING SUCCESSFULLY IMPLEMENTED TO REACH WOMEN AT ELEVATED RISK FOR HIV TESTING AND PREVENTION SERVICES - BUT PEER MODELS HAVE NOT YET BEEN DEPLOYED TO DELIVER BIOMEDICAL PREVENTION CHOICES. IN THIS APPLICATION, WE PROPOSE TO OPTIMIZE AND TEST A PEER- LED DYNAMIC CHOICE HIV PREVENTION INTERVENTION TO CATALYZE CHOICE AND USE OF BIOMEDICAL PREVENTION PRODUCTS. WE WILL TEST THE HYPOTHESIS THAT PEER-LED DYNAMIC CHOICE HIV PREVENTION (WITH CHOICE OF ORAL PREP, DVR, CAB-LA, PLUS LOW-BARRIER PEP ACCESS) WILL INCREASE BIOMEDICAL PREVENTION COVERAGE COMPARED TO STANDARD OF CARE AMONG WOMEN AT ELEVATED HIV RISK IN SOUTHWESTERN UGANDA. THE PROPOSED AIMS ARE: 1) TO REFINE AND OPTIMIZE THE PEER-LED DYNAMIC CHOICE HIV PREVENTION INTERVENTION; 2) TO DETERMINE THE EFFECT OF THE PEER-LED DYNAMIC CHOICE HIV PREVENTION INTERVENTION ON BIOMEDICAL PREVENTION COVERAGE IN A HYBRID TYPE 1 EFFECTIVENESS-IMPLEMENTATION CLUSTER RANDOMIZED TRIAL; 3) TO ASSESS COSTS, EFFICIENCY, AND COST-EFFECTIVENESS OF PEER-LED DYNAMIC CHOICE HIV PREVENTION. COLLECTIVELY, THESE AIMS WILL PROVIDE EVIDENCE FOR PEER-LED MODELS TO DELIVER CHOICE OF HIV PREVENTION PRODUCTS FOR WOMEN AT ELEVATED HIV RISK TO ENHANCE HIV PREVENTION COVERAGE USING PREP, DVR, CAB-LA, AND NEXT-GENERATION PREVENTION MODALITIES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $377.1k | 4/15/26 | ||
| Not listed | $278.8k | 4/3/26 | ||
| Not listed | $309.5k | 9/16/25 | ||
| Not listed | $309.5k | 9/16/25 | ||
| Not listed | $348.0k | 9/11/25 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
16415SCS | Infectious Diseases Research Collaboration | Project Grant R01MH137799 | $309.5k | 3/6/26 | |
15789SCS | Infectious Diseases Research Collaboration | Project Grant R01MH137799 | $180.8k | 2/28/25 |